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1607-551X/Copyright ª 2014, KaohsiuAbstract The effects of a large-piece of xenogeneic bone that was separated from healthy
pigs as a scaffold for the repair of a mandibular defect was investigated, and the applicability
of antigen-extracted xenogeneic cancellous bone (AXCB) soaked with recombinant human
bone morphogenetic protein-2 (rhBMP-2) in bone defect repair was assessed. Mandibular de-
fects were created in 48 New Zealand rabbits, and the animals were randomly divided into four
groups, in which the mandibular defects were grafted with AXCB, AXCB soaked with rhBMP-2,
and autograft bone, or left blank. An equal number of animals from each group were classified
into three time points (4, 8, and 12 weeks) after surgery for gross pathological observation,
hematoxylin and eosin (H and E) staining, radiographic examination, and bone density mea-
surement. H and E staining revealed that the area percentage of bone regeneration in the
group of the AXCB/rhBMP-2 graft was 27.72  4.68, 53.90  21.92, and 77.35  9.83 at 4
weeks, 8 weeks, and 12 weeks, respectively. These results were better than those of the
autogenous bone graft, suggesting that the group of the AXCB/rhBMP-2 graft achieved a good
osteogenic effect. With regard to the AXCB graft without rhBMP-2, the area percentage of
bone regeneration was only 14.03  5.02, 28.49  11.35, and 53.90  21.92. Therefore, the
osteogenic effect of the AXCB/rhBMP-2 graft was demonstrated to have the best effect. In
the group of the AXCB/rhBMP-2 graft, the area percentage of bone regeneration increased,eclare no conflicts of interest.
tre of Stomatology, First Affiliated Hospital of Jinan University, 613 Huangpu Road West, Guangzhou
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rhBMP-2 enhances bone regeneration of xenogeneic bone graft 19and the implanted materials were gradually degraded and replaced by autogenous bone regen-
eration over time. We conclude that the AXCB graft soaked with rhBMP-2 showed good osteo-
genic effect in the repair of bone defects and good biocompatibility. AXCB serves as a good
carrier of rhBMP-2, which promotes bone formation.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Large bone defects in the oral and maxillofacial region are
frequently seen in human patients, and the proper repair of
such defects is challenging due to the anatomical
complexity of this region and the associated cosmetic is-
sues. The primary method to repair the bone defect is bone
transplantation, which includes autologous bone graft,
bone allograft, and xenograft. Autologous bone graft pro-
vides not only a scaffold but also a certain number of os-
teoblasts, and it has the best osteogenic effect. Therefore,
it is considered the gold standard for bone defect repair
[1e3]. The autologous cancellous bone is usually taken
from the iliac cancellous bone, the distal femur, the
greater trochanter, or the proximal tibia [4]. However,
autologous bone graft has limitated bone sources, and it
requires a second operation area, which increases trauma
to patients and the duration of operation [5]. Bone allograft
is another way of providing a scaffold for bone regenera-
tion, but it may carry a high risk of disease transmission. In
addition, ethical issues may also limit the clinical applica-
tion of allogeneic bone graft [6,7]. Xenograft is a good
source of scaffold for bone regeneration, and the most
frequently used, but it is associated with a potential risk of
disease transmission (e.g., bovine spongiform encephalop-
athy from bovine bone xenograft). Nevertheless, with the
development of the advanced specific-antigen-extraction
technology, the risk of disease transmission from xeno-
graft is no longer a health concern [8]. Repairing bone de-
fects with tissue engineering has been the focus of many
studies. One of the significant findings is that the addition
of appropriate growth factors may promote bone defect
repair by accelerating the process of bone induction or
formation. It is widely accepted that bone morphogenetic
protein-2 (BMP-2) induces osteogenesis by promoting the
differentiation of both mesenchymal cells and the bone
marrow precursor cells inside the bone marrow into chon-
drocytes and osteoblasts, and it may also accelerate bone
tissue regeneration and repair [9,10]. However, the po-
tential synergistic effect of BMP-2 and xenogeneic bone in
osteogenesis has not been well explored. Recombinant
human BMP-2 (rhBMP-2) acts as an essential factor in bone
regeneration for mandibular defect repair. rhBMP-2 has
been demonstrated to have bone-induction activity, which
can stimulate bone growth naturally in the human body.
Using a suitable scaffold for carrying rhBMP-2 seems to play
a key role in the procedure. However, thus far, there is no
recognized scaffold that is accepted for clinical use. In this
study, we investigated the biocompatibility of antigen-
extracted xenogeneic cancellous bone (AXCB) as a scaf-
fold and its osteogenic efficiency, in combination withrhBMP-2 (AXCB/rhBMP-2), in repairing defects of the
mandibular bone in rabbits. We aim to identify a better new
approach for bone defect repair in the oral and maxillofa-
cial region using the allogeneic bone as a scaffold.
Materials and methods
The experiments were performed in 48 adult male New
Zealand white rabbits weighing 3.0e3.5 kg. All experi-
mental procedures were performed in accordance with the
Guidelines for the Care and Use of Laboratory Animals
published by the U.S. National Institutes of Health. The
study protocol was approved by the Institutional Animal
Care and Use Committee at Jinan University Health Science
Center, Guangzhou, China.
Preparation of AXCB
The iliac bones were separated from healthy pigs, and cut
into 15 mm  6 mm  4 mm pieces for the preparation of
AXCB. The bone pieces were soaked in acetone for 48 hours
to remove the fatty composition, demineralized in 0.6M
hydrochloric acid, completely washed with water, treated
with epoxide as a crosslinking fixative material for collagen
crosslinking fixation, washed with water again (Fig. 1A),
and then freeze-dried to prepare them for rhBMP-2 incor-
poration. The rhBMP-2 was produced by recombinant
expression in Escherichia coli at the Institute of Biomedical
Engineering, Jinan University (Guangzhou, China), and pu-
rified to >98%. It was then dissolved in gelatin solution with
0.1% acetic acid (10 mg/mL). The biological activity of the
rhBMP-2 was tested before use. Each piece of AXCB was
soaked in 1 mL of gelatin solution containing rhBMP-2
(2.0 mg/mL) for 24 hours, sterilized by gamma-ray irradi-
ation with a radiation dosage of 25 kGy, then freeze-dried
and stored frozen until use (Fig. 1B).
Animal experiment
Forty-eight adult New Zealand white rabbits weighing
3.0e3.5 kg (obtained from the Experimental Animal Center of
Guangdong Province) were randomly divided into four groups
(AXCB graft with rhBMP-2, AXCB graft only, autologous
bone graft, and nongraft control), with three subgroups (4, 8,
and 12 weeks) for each group (4 animals for each condition).
In the autologous bone graft group, bilateral abdominal
incisions parallel to the iliac crest were performed. A
15 mm 6 mm 4 mm bone piece was excised from the iliac
boneoneach side, and then placed in saline solution until use.
Preparation of the AXCB and soaking with rhBMP-2 were
Figure 1. Implantation of AXCB incorporated with rhBMP-2 in a mandibular defect in rabbits. (A) The prepared AXCB. (B) AXCB
scaffold incorporated with rhBMP-2. (C) Creation of a 15 mm  6 mm  6 mm mandibular defect; (D) Implantation of AXCB/rhBMP-2
into the created mandibular defect. AXCBZ antigen-extracted xenogeneic cancellous bone; rhBMP-2Z recombinant human bone
morphogenetic protein-2.
Table 1 Scoring criteria based on the LaneeSandhu
scoring method.
Item Classification Score
Bone
formation
No new bone formation 0
New bone occupied 25% of the defect 1
New bone occupied 50% of the defect 2
New bone occupied 75% of the defect 3
Bone
union
Clear fracture line 0
Fuzzy fracture line 2
Disappeared fracture line 4
Bone
modeling
No bone modeling 0
Marrow cavity formed 2
Cortical bone modeling 4
20 Z.-j. Li et al.performed as described earlier. A bone defect of
15 mm  6 mm  4 mm was then created on both mandibles
for all animals in the four groups (Fig. 1C). In the graft groups,
the bone defect created was implanted with the prepared
AXCB soaked with rhBMP-2, AXCB only, or with autologous
bone (Fig. 1D), whereas in the control (nongraft) group, the
skin incision was directly closed with sutures after the crea-
tion of the bone defect. All animals were then housed under
the same conditions and monitored for postoperative activ-
ities, emotional response, and wound healing. The animals
were killed by excessive carbon dioxide asphyxiation at 4
weeks, 8 weeks, or 12 weeks after the surgery, and the whole
mandible was harvested from each side for investigation.
X-ray examination
X-ray examination of the harvested mandibles was per-
formed (DR3000; Kodak, Rochester, NY, USA), and the im-
aging data were scored based on the LaneeSandhu scoring
method by three technicians who were blinded to the data
[11]. The scoring criteria are presented in Table 1. The
Leica Image Analysis System (Leica, Inc., Solms, Germany)
was used for the assessment of bone regeneration following
the mandibular defect.Bone mineral density measurement
The obtained bone samples were fixed with formalin in
phosphate buffer, and bone mineral density was measured
for the repaired area using the bone density meter platform
Lunar Prodigy (GE, Fairfield, CT, USA). The bone mineral
content is presented as mm/cm3.
rhBMP-2 enhances bone regeneration of xenogeneic bone graft 21Preparation of bone samples for pathological
staining
The obtained bone samples were decalcified, embedded in
paraffin, sectioned into 3-mm slices, and mounted onto
slides for hematoxylin and eosin (H and E) staining. The
stained slides were observed under optical microscope at
100 magnification for evaluation of new bone formation
and calcification, new blood vessel and fibrous tissue gen-
eration, inflammatory cell infiltration, and implanted
scaffold degradation.
Quantitative analysis of the new bone
The bone samples were fixed in 10% neutral buffered
formalin, immersed in Technovit 7200VLC (Heraeus-Kulzer,
Germany) after dehydration, and sectioned into five thin
slices of approximately 40e80 mm and mounted onto slides
after solidification for 24 hours. The slides were H and E
stained, and histomorphometry was performed using the
Leica Image Analysis System (Leica, Inc., Solms, Germany).
Statistical analysis
All results are presented as the mean  standard deviation.
The data were compared and intergroup differences wereFigure 2. X-ray images of the rabbit mandible defect. (A) A repre
(B) A representative result at 4 weeks after the surgery in the AXC
margin of the AXCB graft and the AXCB/rhBMP-2 graft; in addition,
autologous bone and the implanted AXCB/rhBMP-2 graft. (C) A repre
(D) A representative result at 8 weeks after the surgery in the AXC
margin of the AXCB graft and the AXCB/rhBMP-2 graft, and the b
implanted AXCB/rhBMP-2 graft was observed to be obvious, and it w
result at 12 weeks after the surgery in the AXCB group. (F) A rep
rhBMP-2 group. A much fuzzier boundary was observed around the m
fusion between the surrounding autologous bone and the implanted
much clearer than that in the AXCB graft group. (G) A representativ
density shadow with a size of approximately 10 mm  5 mm was cle
surgery in the autograft group. A fuzzy boundary was observed. A
2 Z recombinant human bone morphogenetic protein-2.analyzed using one-way analysis of variance with post hoc
Bonferroni test, and the variance ratio (F ) was calculated.
Statistical analyses were performed using SPSS version 13.0
software (SPSS, Inc., Chicago, IL, USA). A p value < 0.05
was taken to be statistically significant.
Results
Although all rabbits became awake on the day the surgery
was performed, they had reduced activity and limited food
intake. However, their activity and food intake returned to
normal 1e2 days after the surgery. All surgical wounds
healed without swelling and oozing, and the sutures were
taken out 7 days after the surgery. The rabbits in each
group then showed slowly increasing body weight, activity,
and food intake. Neither signs of loss, displacement, and
discharge of the implants nor fracture or wound infection
was observed during the observation period.
Radiographic evaluation
We used lateral and vertical radiography to evaluate bone
regeneration and healing of the mandible defect during
follow up. As shown in Fig. 2, a clear boundary was
observed around the margin of the AXCB graft and the
AXCB/rhBMP-2 graft 4 weeks after the surgery; in addition,sentative result at 4 weeks after the surgery in the AXCB group.
B/rhBMP-2 group. A clear boundary was observed around the
we also observed limited bony fusion between the surrounding
sentative result at 8 weeks after the surgery in the AXCB group.
B/ rhBMP-2 group. A fuzzy boundary was observed around the
ony fusion between the surrounding autologous bone and the
as much clearer than the AXCB graft group. (E) A representative
resentative result at 12 weeks after the surgery in the AXCB/
argin of the AXCB graft and the AXCB/rhBMP-2 graft. The bony
AXCB/rhBMP-2 graft was clearly observed. The bony fusion was
e result at 12 weeks after the surgery in the blank group. A low-
arly observed. (H) A representative result at 12 weeks after the
XCB Z antigen-extracted xenogeneic cancellous bone; rhBMP-
22 Z.-j. Li et al.we also observed limited bony fusion between the sur-
rounding autologous bone and the implanted AXCB/rhBMP-2
graft (Figs. 2A and 2B). Eight weeks after the surgery, a
fuzzy boundary was observed around the margin of the
AXCB graft and the AXCB/rhBMP-2 graft, and the bony
fusion between the surrounding autologous bone and the
implanted AXCB/rhBMP-2 graft was observed very clearly.
This bony fusion was much clearer than that observed in the
AXCB graft group (Figs. 2C and 2D). Twelve weeks after the
surgery, a much fuzzier boundary was observed around the
margin of the AXCB graft and the AXCB/rhBMP-2 graft. The
bony fusion between the surrounding autologous bone and
the implanted AXCB/rhBMP-2 graft was observed very well,
and was much clearer than that in the AXCB graft group
(Figs. 2E and 2F). A low-density shadow of approximately
10 mm  5 mm was clearly observed in the blank group 12
weeks after the surgery (Fig. 2G). With regard to the
autograft group, a fuzzy boundary was observed 12 weeks
after the surgery (Fig. 2H). The bone density of the AXCB/
rhBMP-2 graft group increased with time according to the
observation of the radiography results. New bone formation
was assessed by the LaneeSandhu scoring method. The
average scores were: 1.00, 7.50, and 11.00 in the autograft
group; 1.00, 5.25, and 7.50 in the AXCB/rhBMP-2 group; and
0.20, 2.75, and 3.75 in the AXCB-alone group at 4 weeks, 8
weeks, and 12 weeks after the surgery, respectively, which
indicated that the scaffold graft alone had a limited effect
on bone regeneration and that the addition of rhBMP-2
greatly enhanced bone regeneration, comparable to the
autogenous bone graft (Table 2). New bone generation
increased over time.
Bone mineral density
A bone mineral density test revealed significant differences
in bone mineral density across the groups 12 weeks after
the surgery (autogenous bone group > xenogeneic AXCB/
rhBMP-2 group > xenogeneic AXCB-only group; p < 0.05).
Moreover, the bone mineral density significantly increased
over time (at 4, 8, and 12 weeks) within the AXCB/rhBMP-2
graft group and the autograft group (p < 0.05; Table 3).
Histological observation
In the group with implantation of AXCB, at 4 weeks after
the surgery, some fibrous tissue, capillary proliferation,
trace of trabecular bone degradation, a small number of
osteoblasts, and a small amount of new bone formation
were found around the edge of the implant (Fig. 3A). At 8Table 2 Average scores of bone regeneration in each group ba
Groups 4 wks after surgery
AXCB graft group 0.20  0.00
AXCB/rhBMP-2 graft group 1.00  1.16a,*
Autograft group 1.00  0.43
*p < 0.05.
AXCB Z antigen-extracted xenogeneic cancellous bone; rhBMP-2 Z r
a Versus the AXCB graft group at 4 weeks, 8 weeks, and 12 weeks a
b Versus 4 weeks and 8 weeks after the surgery in the AXCB/rhBMPweeks after the surgery, there was partial degradation of
trabecular bone; in addition, a large number of osteoblasts
around the edge of the implant were observed (Fig. 3B). At
12 weeks after the surgery, there was a small amount of
matured trabecular bone tissue (Fig. 3C). In the group with
implantation of AXCB soaked with rhBMP-2, at 4 weeks
after the surgery, the trabecular bone of the implant was
partially degraded, extensive new bone formation was
observed, and around the new bone, there were a large
number of osteoblasts and mesenchymal cells, capillary
ingrowth, and osteoid formation (Fig. 3D). At 8 weeks after
the surgery, there was a small area of unabsorbed implant,
a large amount of trabecular bone tissue and new bone
formation, and capillary ingrowth, with many surrounding
osteoblasts and mesenchymal cells (Fig. 3E). At 12 weeks
after the surgery, there was almost complete degradation
of the implant, as well as a large amount of new bone
formation with mature trabecular bone and some bone
marrow (Fig. 3F). Histological examination showed rigorous
bone regeneration around the implant. In the nongraft
control group, the mandible showed only a small amount of
new bone formation, and the created bone defect was
mainly occupied by fibrous tissue at 12 weeks after the
surgery (Fig. 3G). In the autograft group, a large amount of
new mature trabecular bone was seen, and the mandibular
defect was mostly occupied by the newly formed bone
(Fig. 3H).
Quantitative assessment of bone regeneration
The percentage of area with new bone formation was
calculated under microscopic view of the H and E-stained
slides. Statistical analysis suggested that the area of bone
regeneration in the mandibular defect was significantly
greater in the AXCB/rhBMP-2 graft group than in the AXCB
graft group (p < 0.05), and there was no significant dif-
ference in the area of new bone formation between the
autograft group and the AXCB/rhBMP-2 graft group
(p > 0.05). There was a significant increase of bone
regeneration over time (at 4, 8, and 12 weeks after the
surgery) within the AXCB/rhBMP-2 graft group and the
autograft group (p < 0.05; Table 4).Discussion
Tumors, especially malignant tumors, severe trauma, and
congenital malformations in the oral and maxillofacial re-
gion often lead to a large area of bone defect. Because ofsed on the LaneeSandhu scoring method.
8 wks after surgery 12 wks after surgery
2.75  0.50 3.75  0.50
8.25  0.50a,* 10.50  1.00a,b,*
9.50  0.76 11.00  1.23b,*
ecombinant human bone morphogenetic protein-2.
fter the surgery.
-2 graft group and the autograft group.
Figure 3. Histological images of the rabbit mandible defect (100). (A) A representative result at 4 weeks after the surgery in
the AXCB group. Some fibrous tissue, capillary proliferation, a trace of trabecular bone degradation, a small number of osteoblasts,
and a small amount of new bone formation were found around the edge of the implant. (B) A representative result at 4 weeks after
the surgery in the AXCB/ rhBMP-2 group. The trabecular bone of the implant was partially degraded, extensive new bone formation
was observed, and around the new bone there were a large number of osteoblasts and mesenchymal cells, capillary ingrowth, and
osteoid formation. (C) A representative result at 8 weeks after the surgery in the AXCB group. There was partial degradation of
trabecular bone, and also a large number of osteoblasts around the edge of the implant. (D) A representative result at 8 weeks
after the surgery in the AXCB/rhBMP-2 group. There was a small area of unabsorbed implant, a large amount of trabecular bone
tissue and new bone formation, and capillary ingrowth, with many surrounding osteoblasts and mesenchymal cells. (E) A repre-
sentative result at 12 weeks after the surgery in the AXCB group. There was a small amount of matured trabecular bone tissue. (F) A
representative result at 12 weeks after the surgery in the AXCB/ rhBMP-2 group. There was almost complete degradation of the
implant, as well as a large amount of new bone formation with mature trabecular bone and some bone marrow. (G) A represen-
tative result at 12 weeks after the surgery in the blank group. The mandible showed only a small amount of new bone formation,
and the created bone defect was mainly occupied by fibrous tissue at 12 weeks after the surgery. (H) A representative result at 12
weeks after the surgery in the autograft group. A large amount of new mature trabecular bone was seen, and the mandibular
defect was mostly occupied by the newly formed bone. AXCB Z antigen-extracted xenogeneic cancellous bone; rhBMP-
2 Z recombinant human bone morphogenetic protein-2.
Table 3 Bone mineral density of the animals in each group at 4 weeks, 8 weeks, 12 weeks after the surgery.
Groups 4 wks after surgery 8 wks after surgery 12 wks after surgery
AXCB graft group 195.03  12.36 223.31  28.17 231.43  21.96
AXCB/rhBMP-2 graft group 223.13  20.45 250.62  14.87 326.85  33.70a,b,*
Autograft group 241.19  13.57 277.65  26.70 351.10  3785b,*
Data are presented as milligram/cubic centimeter.
*p < 0.05.
AXCB Z antigen-extracted xenogeneic cancellous bone; rhBMP-2 Z recombinant human bone morphogenetic protein-2.
a Versus the AXCB graft group and the autograft group at 12 weeks after the surgery.
b Versus 4 weeks and 8 weeks after the surgery in the AXCB/rhBMP-2 graft group and the autograft group.
Table 4 Percentage of area with new bone formation in each group at 4 weeks, 8 weeks, 12 weeks after the surgery.
Groups 4 wks after surgery 8 wks after surgery 12 wks after surgery
AXCB graft group 14.03  5.02 28.49  11.35 55.87  10.20
AXCB/rhBMP-2 graft group 27.72  4.68a,* 53.90  21.92a,* 77.35  9.83a,b,*
Autograft group 30.19  1.46 49.73  2.68 68.18  3.92b,*
*p < 0.05.
AXCB Z antigen-extracted xenogeneic cancellous bone; rhBMP-2 Z recombinant human bone morphogenetic protein-2.
a Versus the AXCB graft group at 4 weeks, 8 weeks, 12 weeks after the surgery.
b Versus 4 weeks, 8 weeks after the surgery in the AXCB/rhBMP-2 graft group and the autograft group.
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complexity, the restoration of bone defects in the oral and
maxillofacial region remains a challenge for surgeons. The
restoration of the original shape of the facial skull is a
prerequisite for the restitution of facial appearance. Sur-
geons are trying to develop new approaches for the
enhancement of bone regeneration to replace autogenous
bone grafts. Recent progress in regenerative medicine and
bone tissue engineering raises the hope of repairing bone
defects with a combination of biomaterials and growth
factors. Application of the large cancellous bone (ilium) as
a morphogen carrier for rhBMP-2 in skeletal repair has been
extensively studied during the past decade [12,13]. It is
widely accepted that BMP-2 induces osteogenesis by pro-
moting the differentiation of both mesenchymal cells and
the bone marrow precursor cells inside the bone marrow
into chondrocytes and osteoblasts, and it may also accel-
erate bone tissue regeneration and repair. BMPs have been
successfully applied in the reconstruction of long bones,
spine, and the facial skeleton in preclinical studies [14].
At present, a large number of animal experiments and
in vitro experiments confirmed that rhBMP-2 does not cause
systemic toxicity, cytotoxicity, or cell mutagenicity. The
earliest application of rhBMP-2 in the clinical setting was in
a lumbar interbody fusion device. This randomized study
included 14 patients, each of whom was implanted with
two lumbar interbody fusion devices with rhBMP-2 at a dose
of 1.5 mg/mL by the retroperitoneal and transperitoneal
approach. Significant differences of Oswestry scores were
found between the experimental group and the control
group before and after the surgery at 3 months, 6 months,
12 months, and 24 months, respectively, using X-ray and
computed tomography examinations [15]. Villavicencio
et al [16] reported a clinical observation on 74 patients who
underwent a lumbar interbody fusion operation using
rhBMP-2/gelatin sponge or allograft. The radiographic spi-
nal fusion rate in their study was 100% at 12 months and 24
months after the surgery, respectively, and no rhBMP-2-
related complications, such as bone overgrowth, ectopic
bone, nerve damage, and other complications were
observed. In addition, rhBMP-2 has not been found to pro-
mote the growth of tumor cells. These studies have pro-
vided a theoretical basis that the rhBMP-2 can be safely and
effectively used for clinical treatment. However, rhBMP-2 is
an exogenous cell growth factor, and therefore its clinical
application in supraphysiological doses has the potential
risks of soft-tissue edema, skin rash, inflammation reaction,
heterotopic ossification, and adverse immune response
consequences. Therefore, the safe use of rhBMP-2 for
human patients still needs long-term preclinical and clinical
studies. In addition, there are also some problems that
should be resolved to achieve the ideal effect of bone
regeneration enhanced by rhBMP-2 in clinical and scientific
research. On the one hand, pure rhBMP-2 in vivo can be
rapidly decomposed and diluted by protease inhibitors.
Various studies have shown that rhBMP-2 in vivo can
decompose within a few hours after implantation, and
therefore, it has only a very limited time to maintain the
effective concentration in vivo [17]. It was widely recog-
nized that the local concentration of rhBMP-2 was of more
clinical value than the total dose. The present research has
not determined the therapeutic use of high rhBMP-2concentrations in the nonhuman primate animal body. A
concentration in the range of 0.4e1.5 mg/mL has been
applied in long bone trauma patients. On the other hand,
pure rhBMP-2 itself does not have any filling, supporting, or
other mechanical properties, and therefore, it cannot
directly fill into the bone defect, which seriously restricts
the bone repair effect. At present, many vehicles have
been used as rhBMP-2 carriers, including polymer ceramic,
bone cement, polymer, collagen, chitosan, hyaluronic acid,
allograft, and xenograft.
Based on the theory of creeping substitution [18e20], an
ideal bone graft used for bone defect repair should provide
a platform for the three essential elements of bone
regeneration (i.e., osteoinduction, osteoconduction, and
osteogenesis). Osteoinduction is a process of inducing dif-
ferentiation of mesenchymal stem cells into osteoblasts
and chondrocytes, presumably by some morphogens.
Osteoconduction is a property of the bone graft as a scaf-
fold that conducts the ingrowth of the osteoblasts (differ-
entiation and maturation) as well as that of the blood
vessels, providing a platform for osteogenesis. The scaffold
graft is gradually replaced by creeping substitution of the
newly regenerated bone [21]. Some studies have shown
that the creeping substitution occurs mainly in the facial
layer and at the two ends of the implanted bone. Large
bone defects may have very limited regeneration using
heterologous bone graft. BMPs are good morphogens that
induce both osteogenesis and angiogenesis [22,23], which
may help to overcome the aforementioned limitation of
large heterologous bone graft. rhBMP-2 is the growth factor
most widely used for bone regeneration [24], but it diffuses
quickly after application. Therefore, the development of
favorable carriers with slow-releasing properties is critical.
The bone morphology of the oral and maxillofacial re-
gion in rabbits has similarities to that observed in humans.
In this study, we soaked the rhBMP-2 into a piece of AXCB,
which was then implanted into the bone defect of the same
size created in the mandibles of New Zealand white rabbits,
and subsequently assessed the bone regenerative effect
[25]. The results revealed that the AXCB/rhBMP-2 graft
group had much better and more extensive bone regener-
ation than the group grafted with AXCB only; in addition,
the bone regeneration increased over time from 4 weeks to
12 weeks after the surgery, which indicated that rhBMP-2
had a significant bone regenerative effect over time with
AXCB as a scaffold and that AXCB is probably a good carrier
for rhBMP-2, allowing for the slow release of rhBMP-2 and
thus improving its efficiency. By contrast, the AXCB was
found to become gradually degraded over time, and at 12
weeks after the surgery, the implanted bone was almost
completely replaced by newly regenerated bone tissue,
which showed an apparent mature trabecular structure.
There were no appreciable histological signs of inflamma-
tion or immune rejection of the graft, suggesting the good
biocompatibility of AXCB.Conclusion
In conclusion, the osteogenic effect of the AXCB graft
soaked with rhBMP-2 proved to be much better than the
AXCB graft alone (without rhBMP-2), which showed no
rhBMP-2 enhances bone regeneration of xenogeneic bone graft 25significant difference with the autologous bone graft. The
porous AXCB appears to be a good carrier for rhBMP-2,
which allows for controlled release of rhBMP-2 to a certain
extent. Antigen-extracted xenogeneic pig massive cancel-
lous bone has shown good biocompatibility and it may
potentially replace autologous bone graft in repairing large
bone defects. This study has provided a new reference for
bone regeneration in the oral and maxillofacial region.
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